DiaMedica Therapeutics (NASDAQ:DMAC) Raised to “Hold” at Wall Street Zen

DiaMedica Therapeutics (NASDAQ:DMAC) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.

A number of other equities research analysts have also issued reports on DMAC. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of DiaMedica Therapeutics in a report on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Thursday, October 15th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $12.00.

DiaMedica Therapeutics Stock Performance

Shares of DiaMedica Therapeutics stock opened at $8.72 on Friday. DiaMedica Therapeutics has a 52-week low of $5.24 and a 52-week high of $10.42. The company’s 50 day moving average price is $7.35 and its 200-day moving average price is $6.77. The stock has a market capitalization of $470.27 million, a price-to-earnings ratio of -12.11 and a beta of 0.92.

DiaMedica Therapeutics (NASDAQ:DMAC) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.01. As a group, equities research analysts forecast that DiaMedica Therapeutics will post -0.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DiaMedica Therapeutics

A number of large investors have recently made changes to their positions in DMAC. Squarepoint Ops LLC purchased a new stake in shares of DiaMedica Therapeutics in the 2nd quarter worth about $1,023,000. AWM Investment Company Inc. bought a new stake in shares of DiaMedica Therapeutics during the 2nd quarter valued at about $253,000. Bank of New York Mellon Corp bought a new stake in shares of DiaMedica Therapeutics during the 2nd quarter valued at about $829,000. Bank of America Corp DE increased its position in shares of DiaMedica Therapeutics by 62.5% during the first quarter. Bank of America Corp DE now owns 42,768 shares of the company’s stock valued at $290,000 after buying an additional 16,446 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in shares of DiaMedica Therapeutics during the first quarter valued at about $356,000. 10.12% of the stock is currently owned by institutional investors.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious diseases affecting the kidneys and nervous system. The company’s research is centered on therapies intended to address conditions with limited treatment options.

DiaMedica’s lead investigational product is DM199, a recombinant form of human tissue kallikrein-1, an enzyme involved in blood flow regulation and vascular function. The company has evaluated DM199 in clinical development programs targeting acute ischemic stroke and kidney-related diseases, including chronic kidney disease.